The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms. In a prospective naturalistic observational study, 42 patients with Alzheimer's disease (AD) and AD with cerebrovascular disease who took donepezil (10 mg) for 12 months were evaluated. Their DNA was genotyped, and the donepezil plasma concentrations were measured after 3, 6, and 12 months. Good responders scored ≥-1 on the Mini-Mental State Examination at 12 months in comparison to the baseline score. The study results indicated the good response pattern was influenced by the concentration of donepezil, but not by APOE and CYP2D6 polymorphisms.
A higher rate of good response was observed in this study compared to that in previous investigations. The pharmacogenetic aspects do not seem to have an influence in the response.
Life expectancy in Brazil has increased markedly over the last 30 years. Hence,
age-related disorders, such as Alzheimer's disease (AD), warrant special
attention due to their high prevalence in the elderly. Pharmacologic treatment
of AD is based on cholinesterase inhibitors (ChEI) and memantine, leading to
modest clinical benefits both in the short and long-term. However, clinical
response is heterogeneous and needs further investigation.OBJECTIVETo investigate the rate of response to ChEI in AD after three months of
treatment.METHODSPatients with mild or moderate dementia due to probable AD or to AD
associated with cerebrovascular disease were included in the study. The
subjects were assessed at baseline and again after three months of ChEI
treatment. Subjects were submitted to the Mini-Mental State Examination
(MMSE), Mattis Dementia Rating Scale, Katz Basic Activities of Daily Living,
Pfeffer Functional Activities Questionnaire, Neuropsychiatric Inventory and
Cornell Scale for Depression in Dementia. Good response was defined by a
gain of ≥2 points on the MMSE after three months of treatment in
relation to baseline.RESULTSSeventy-one patients, 66 (93%) with probable AD and five (7%) with AD
associated with cerebrovascular disease, were evaluated. The good response
rate at three months was 31.0%, being 37.2% and 21.4% in mild and moderate
dementia, respectively. There were no significant differences on most tests,
except for improvement in hallucinations, agitation and dysphoria in
moderate dementia patients.CONCLUSIONThe rate of good clinical response to ChEI was higher than usually reported.
Specific behavioral features significantly improved in the subgroup of
moderate dementia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.